IL39078A - Pharmaceutical compositions containing 16-lower alkyl or 16,16-diloweralkyl prostaglandins of the a and e types - Google Patents
Pharmaceutical compositions containing 16-lower alkyl or 16,16-diloweralkyl prostaglandins of the a and e typesInfo
- Publication number
- IL39078A IL39078A IL39078A IL3907872A IL39078A IL 39078 A IL39078 A IL 39078A IL 39078 A IL39078 A IL 39078A IL 3907872 A IL3907872 A IL 3907872A IL 39078 A IL39078 A IL 39078A
- Authority
- IL
- Israel
- Prior art keywords
- pge2
- pgei
- preparation
- methyl
- pga2
- Prior art date
Links
- 125000000217 alkyl group Chemical group 0.000 title claims 3
- 229940094443 oxytocics prostaglandins Drugs 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 150000003180 prostaglandins Chemical class 0.000 title 1
- 229960002986 dinoprostone Drugs 0.000 claims abstract 8
- 150000003839 salts Chemical class 0.000 claims abstract 2
- 238000007910 systemic administration Methods 0.000 claims abstract 2
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 claims 7
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 claims 6
- -1 PGAX Chemical compound 0.000 claims 5
- 101100310593 Candida albicans (strain SC5314 / ATCC MYA-2876) SOD4 gene Proteins 0.000 claims 4
- MYHXHCUNDDAEOZ-UHFFFAOYSA-N Prostaglandin A&2% Natural products CCCCCC(O)C=CC1C=CC(=O)C1CC=CCCCC(O)=O MYHXHCUNDDAEOZ-UHFFFAOYSA-N 0.000 claims 4
- 101100190148 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) PGA2 gene Proteins 0.000 claims 4
- MYHXHCUNDDAEOZ-FOSBLDSVSA-N prostaglandin A2 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1C=CC(=O)[C@@H]1C\C=C/CCCC(O)=O MYHXHCUNDDAEOZ-FOSBLDSVSA-N 0.000 claims 4
- 150000002148 esters Chemical class 0.000 claims 3
- 241000124008 Mammalia Species 0.000 claims 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- 230000001262 anti-secretory effect Effects 0.000 claims 1
- 230000000767 anti-ulcer Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 150000004702 methyl esters Chemical class 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- QAOBBBBDJSWHMU-WMBBNPMCSA-N 16,16-dimethylprostaglandin E2 Chemical compound CCCCC(C)(C)[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O QAOBBBBDJSWHMU-WMBBNPMCSA-N 0.000 abstract 1
- 239000002775 capsule Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000002496 gastric effect Effects 0.000 abstract 1
- 210000004051 gastric juice Anatomy 0.000 abstract 1
- 230000028327 secretion Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4891—Coated capsules; Multilayered drug free capsule shells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Medicaments in a form suitable for systemic administration contain 16-methyl, 16,16-dimethyl-, 16-ethyl-, 16,16-diethyl- or 16-methyl-16-ethyl-PGE, -PGE2, -PGA1 or -PGA2 in their optically active or racemic forms, or their salts or 1-8C-alkyl esters. Compsns. are capable of ggiving a dose of 0.7-57 mg/kg PG. Thus a capsule contg. 2mg 16,16-dimethyl PGE2 given 1-4 times daily reduces the secretion of gastric juices in a patient showing gastric hypersecretion.
[DE2216717A1]
Claims (1)
1. t28lOA "WHAT IS CLAIMED IS: - 1 - A pharmaceutical preparation in dosage unit form con-sisting essentially of a member selected from the group consisting of the optically active and racemic forms of 16-methyl PGEi, PGE2, PGAX , or PGA2, l6,l6-d imethyl PGEi, PGE2 , PGAi, or PGA2, 16-ethyl PGEi, PGE2, PGAX, or PGA2, l6,l6-diethyl PGEi, PGE2, PGAi , or PGA2 , l6-ethyl-l6-methyl PGEi, PGE2 , PGAi, or PGA2j pharmaceutically acceptable salts thereof , and pharma-ceutically acceptable carboxyiate esters thereof wherein the esterifying radical is lower alkyl having 1 to 8 carbon atoms, inclusive, in combination with pharmaceutical means which adapt the preparation for systemic administration to obtain an antisecretory or antiulcer effect in affected mammals, the amount of said member in said dosage unit form being predetermined to provide to the affected mammal a dose of the member of from about 0.7 micrograms to about 57 micrograms per kilo. - 2 - The preparation of claim 1 wherein the member is l6,l6^ d imethyl -PGEi , or ΐβ, ΐβ-d imethyl - PGE2. - 3 - The preparation of claim 1 wherein the member is a lower alkyl carboxyiate ester wherein the esterifying radical has 1 to 8 carbon atoms, inclusive. - 4' - The preparation of claim 3 wherein the carboxyiate ester is the methyl ester. 2810A - 5 - The preparation of claim 1 wherein the member is 16-methyl, l6 , ΐβ -d i methy 1 , 16-ethyl, 16, 16-d i ethy 1 or 16-ethy 1 -l6-methy 1 PGEi or PGE2. - 6 - The preparation of claim 1 which is enteric coated. COHE P. O. Box 33116 , Tel-Aviv Attorneys for Appl icant
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US19189971A | 1971-10-22 | 1971-10-22 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL39078A0 IL39078A0 (en) | 1972-05-30 |
| IL39078A true IL39078A (en) | 1976-08-31 |
Family
ID=22707366
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL39078A IL39078A (en) | 1971-10-22 | 1972-03-26 | Pharmaceutical compositions containing 16-lower alkyl or 16,16-diloweralkyl prostaglandins of the a and e types |
Country Status (6)
| Country | Link |
|---|---|
| BE (1) | BE781978A (en) |
| DE (1) | DE2216717C2 (en) |
| IL (1) | IL39078A (en) |
| NL (1) | NL7204870A (en) |
| PH (1) | PH9797A (en) |
| ZA (1) | ZA721937B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3966962A (en) * | 1975-03-27 | 1976-06-29 | The Upjohn Company | Triacetin solutions of PGE-type compounds |
| US4310543A (en) * | 1980-10-09 | 1982-01-12 | Hoffmann-La Roche Inc. | Prostaglandin compositions |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR1584563A (en) * | 1967-06-26 | 1969-12-26 |
-
1972
- 1972-03-21 ZA ZA721937A patent/ZA721937B/en unknown
- 1972-03-26 IL IL39078A patent/IL39078A/en unknown
- 1972-04-03 PH PH13410A patent/PH9797A/en unknown
- 1972-04-07 DE DE2216717A patent/DE2216717C2/en not_active Expired
- 1972-04-12 BE BE781978A patent/BE781978A/en not_active IP Right Cessation
- 1972-04-12 NL NL7204870A patent/NL7204870A/xx not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| DE2216717C2 (en) | 1984-05-17 |
| NL7204870A (en) | 1973-04-25 |
| BE781978A (en) | 1972-10-12 |
| ZA721937B (en) | 1972-12-27 |
| PH9797A (en) | 1976-03-17 |
| IL39078A0 (en) | 1972-05-30 |
| DE2216717A1 (en) | 1973-04-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US3903297A (en) | Method of treatment and prophylaxis of gastric hypersecretion and gastric and duodenal ulcers using prostaglandin analogs | |
| US5312818A (en) | Method of protecting against and/or treating ulcerative gastrointestinal conditions using a thromboxane A2 receptor antagonist and combination useful in preventing and/or treating ulcers and/or inflammation | |
| US4272548A (en) | Process for the lowering of increased levels of cholesterol and neutral fat in the blood of humans | |
| US4409239A (en) | Propylene glycol diester solutions of PGE-type compounds | |
| US4746675A (en) | External pharmaceutical composition | |
| AU622276B2 (en) | Medicament containing dihydrolipoic acid as active substance | |
| US5426115A (en) | Use of 15-keto-prostaglandin compound for improvement of encephalic function | |
| Collins et al. | Chemistry and synthetic development of misoprostol | |
| US4310543A (en) | Prostaglandin compositions | |
| US8962688B2 (en) | Method for the treatment of gastrointestinal disorders | |
| KR910019624A (en) | Medicinal prostaglandin analogs | |
| US5252605A (en) | Promotion of wound-healing with 15-keto-prostaglandin compounds | |
| US4684632A (en) | Formulation with special 1,2-diacylglycero-3-phosphocholines for the treatment of gastrointestinal disorders | |
| EP0078434A1 (en) | Pharmaceutical and dietary compositions | |
| US5164415A (en) | Treatment of pancreatic disease with 15-keto-prostaglandin compounds | |
| US4623641A (en) | Method of treating ulcers and erosions in the gastrointestinal system using PGI2 -methyl ester-beta cyclodextrin inclusion complexes | |
| IL39078A (en) | Pharmaceutical compositions containing 16-lower alkyl or 16,16-diloweralkyl prostaglandins of the a and e types | |
| US5324748A (en) | Method for enhancement of 1-series PG production | |
| US5389664A (en) | Alleviating stomach ulcers in swine | |
| IE39239B1 (en) | Cycloalkyl alkyl esters and process for their preparation | |
| CA1197782A (en) | Pharmaceutical and dietary composition | |
| JPS54125653A (en) | Prostaglandin i2 analog, its preparation, and drug composition comprising it as active constituent | |
| AU609250B2 (en) | New medical use for an isocarbacyclin derivative | |
| US5364883A (en) | Isocarbocyclins for the treatment of liver and kidney diseases | |
| IL41868A (en) | Pharmaceutical preparations containing d-penicillamine |